Sign In
Buy MDWD
$13.73
-0.0300 (-0.218%)
At Close: Jun 03, 2026
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
01:57pm, Wednesday, 27'th May 2026
MediWound Ltd. (MDWD) Q1 2026 Earnings Call Transcript
MediWound Q1 Earnings Call Highlights
10:10am, Wednesday, 27'th May 2026
MediWound NASDAQ: MDWD reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance
MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates
09:11am, Wednesday, 27'th May 2026
MediWound (MDWD) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.07 per share a year ago.
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
07:00am, Wednesday, 27'th May 2026
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue
MediWound to Report First Quarter 2026 Financial Results
08:00am, Thursday, 07'th May 2026
MediWound to Report First Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 27 th at 8:30 a.m. Eastern Time YAVNE, Israel, May 7, 2026 -- MediWound Ltd.
Head-To-Head Review: Surrozen (NASDAQ:SRZN) & MediWound (NASDAQ:MDWD)
02:29am, Wednesday, 15'th Apr 2026
Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies ba
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
07:30am, Monday, 13'th Apr 2026
Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement Peer-reviewed consensus redefines debridement from simple tissue removal to a more comprehensive bi
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
07:00am, Tuesday, 07'th Apr 2026
MediWound to Present New EscharEx ® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and comparative advantages over SANTYL ® Findings suppo
Head-To-Head Analysis: MediWound (NASDAQ:MDWD) & Dyne Therapeutics (NASDAQ:DYN)
01:13am, Friday, 03'rd Apr 2026
Dyne Therapeutics (NASDAQ: DYN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses bas
MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
03:26pm, Thursday, 02'nd Apr 2026
MediWound Reports BARDA Contract Award to Vericel for NexoBrid ® Valued at up to $197 Million YAVNE, Israel, April 2, 2026 — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzyma
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
04:55pm, Thursday, 05'th Mar 2026
MediWound Ltd. (MDWD) Q4 2025 Earnings Call Transcript
MediWound Files Annual Report on Form 20-F
04:30pm, Thursday, 05'th Mar 2026
MediWound Files Annual Report on Form 20-F YAVNE, Israel, March 5 , 202 6 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, t oday announce
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates
09:21am, Thursday, 05'th Mar 2026
MediWound (MDWD) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.36 per share a year ago.
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Thursday, 05'th Mar 2026
EscharEx ® Phase III VALUE trial advancing as planned Expanded NexoBrid ® manufacturing facility operational ; regulatory approvals expected in 2026 $17 million revenue in 2025 ; $54 million in cash
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results
08:00am, Thursday, 19'th Feb 2026
MediWound to Report Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Scheduled for Thursday, March 5 th at 8:30 a.m. Eastern Time YAVNE, Israel, February 19, 2026 -- Med
